Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Amit Sanyal, MD: A Clinician’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Dec

Today In Oncology

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Amit Sanyal, MD: A Clinician’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns

Data Published on Incidence of Immune Checkpoint Inhibitor-Associated ITP

Lymphocyte Kinetics After CAR T Infusion Predict Survival Outcomes in Non-Hodgkin Lymphoma

CD123-Targeting ADC Shows Activity in AML and BPDCN